KOSDAQHolding Companies221800

ZGOO Holdings

₩2,905▼ 2.68%2026-11-18 close
Market Cap
₩47.4B
Turnover
₩32,731,510
Volume
10K
Shares out.
16.3M
PER
—
PBR
1.0×
EPS
-₩447
Dividend Yield
3.03%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Rebound, Losses Persist During Holding Transition

Third-quarter 2026 sales rose 55.6% year on year, yet the operating loss widened to KRW 2.22 billion. Whether top-line growth turns into profit recovery is the key open question.

  1. 1

    Third-quarter 2026 sales reached KRW 10.7 billion, up 55.6% year on year, but the operating loss widened to KRW 2.22 billion. Operating losses have continued for five consecutive quarters since the third quarter of 2025.

  2. 2

    The 2025 annual operating loss was KRW 2.36 billion, and the company has posted operating losses from 2023 through 2025. Operating cash flow was negative in each year from 2023 to 2025.

  3. 3

    Second-quarter 2026 sales of KRW 12 billion appear to reflect the consolidation of Neural Arcade and Hanger, and the operating loss narrowed to KRW 549 million in that quarter.

  4. 4

    The sum of attributable net losses for the last four quarters is KRW 6.94 billion. The attributable net loss narrowed from KRW 3.7 billion in the second quarter to KRW 2.28 billion in the third quarter.

  5. 5

    On November 10, 2026, the company announced it had become the largest shareholder of Noul, an AI-based blood and cancer diagnostics company, with the healthcare subsidiaries cited as the bridge to domestic diagnostics.

02

Business structure

ZGOO Holdings is a business and investment holding company built on permanent capital, founded by entrepreneurs with direct experience in startups and investing.

After a spin-off completed on May 1, 2026, the former diagnostics and health IT business U2Bio became an independent subsidiary, and the surviving entity was renamed ZGOO Holdings.

The healthcare cluster centers on U2Bio, which provides in-vitro diagnostic testing services, and a subsidiary that handles clinical trial sample analysis. In April 2026 the company acquired an AI-based consumer content business, adding a consumer-facing segment.

In May 2026 it secured a 43% stake in Hanger, a K-beauty direct-to-consumer cosmetics e-commerce company, and brought it in as a subsidiary through a management takeover. The company treats healthcare as one of its key business areas and says it intends to broaden the portfolio into other fields.

Its acquisition screen targets companies with annual sales of at least KRW 5 billion. The investment model is a 5 to 10% stake first, followed by staged acquisitions, with a shareholder group holding roughly half of the shares and taking part in operations.

In November 2026 it subscribed to new shares in Noul and became the largest shareholder with about a 9.7% stake. With healthcare and consumer subsidiaries now consolidated, the business mix has moved from a diagnostics-centered profile to a more diversified one.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.9B-₩600M−8.5%
2025Q4₩6.3B-₩900M−13.7%
2026Q1₩7B-₩1.6B−22.8%
2026Q2₩12B-₩500M−4.6%
2026Q3₩10.7B-₩2.2B−20.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩69B₩15.7B₩13.2B22.8%38.9%50.8%
2023₩30.8B-₩1.3B₩600M−4.3%1.7%29.5%
2024₩25B-₩3.1B-₩2.8B−12.5%−8.3%30.7%
2025₩25.6B-₩2.4B-₩1.6B−9.2%−3.9%24.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On an annual basis, sales fell from KRW 69 billion in 2022 to KRW 30.8 billion in 2023 (down 55.4% year on year) and to KRW 25 billion in 2024 (down 18.7%), before edging up to KRW 25.6 billion in 2025 (up 2.2%). 2022 was the largest year in the 2022 to 2025 period and 2024 the smallest.

Profitability fell much further than sales. The operating margin moved from 22.8% in 2022 to -4.3% in 2023, -12.5% in 2024 and -9.2% in 2025.

The KRW 15.7 billion operating profit of 2022 turned into an operating loss of KRW 1.34 billion in 2023, widened to KRW 3.13 billion in 2024, and narrowed to KRW 2.36 billion in 2025.

Attributable net income fell from KRW 13.2 billion in 2022 to KRW 646 million in 2023 (down 95.1%), then turned into an attributable net loss of KRW 2.84 billion in 2024 and KRW 1.64 billion in 2025.

Net income including non-controlling interests, which differs from attributable net income, was a net loss of KRW 2.84 billion in 2024 and KRW 1.64 billion in 2025.

Operating cash flow moved from KRW 24.4 billion in 2022 to negative figures of -KRW 2.55 billion in 2023, -KRW 1.73 billion in 2024 and -KRW 1.56 billion in 2025.

The debt ratio declined from 50.8% in 2022 to 24.1% in 2025, with total equity of KRW 42.3 billion and total liabilities of KRW 10.2 billion at year-end 2025.

Quarterly, sales were KRW 6.87 billion in the third quarter of 2025 with an operating loss of KRW 586 million, then KRW 6.27 billion in the fourth quarter (down 8.8% quarter on quarter) with an operating loss of KRW 857 million, and KRW 6.98 billion in the first quarter of 2026 (up 11.4%) with an operating loss of KRW 1.59 billion.

According to the company's briefing material, first-quarter selling and administrative expenses included one-off integration and restructuring costs tied to the launch of ZGOO Holdings and the acquisition of a clinical trial subsidiary, while non-operating items included a KRW 990 million valuation gain on listed shares it holds.

Second-quarter 2026 sales rose to KRW 12 billion (up 72.1%) and the operating loss narrowed to KRW 549 million. Third-quarter sales were KRW 10.7 billion (down 11.0% quarter on quarter, up 55.6% year on year), but the operating loss widened to KRW 2.22 billion from the second quarter.

The attributable net loss narrowed to KRW 2.28 billion in the third quarter from KRW 3.7 billion in the second quarter.

05

Industry analysis

The core of ZGOO Holdings' business is in-vitro diagnostics and clinical trial sample analysis.

Noul, the AI diagnostics company in which ZGOO Holdings holds its largest stake, has built miLab, an integrated diagnostic platform that automates the previously manual microscopy workflow, from sample staining through digital microscope imaging to AI analysis.

ZGOO Holdings plans to combine this technology with the infrastructure its subsidiaries have in domestic hospitals, clinics and clinical trial sites.

Demand for diagnostic testing services and sample analysis tracks hospital testing volumes and clinical trial demand, so client institutions and testing volumes are the key variables for performance.

The field has large diagnostics companies and mid-sized contract testing providers competing, and ZGOO Holdings positions the infrastructure links among its subsidiaries as its differentiator rather than scale.

Unlike SK Square (SK Square), which centers on stakes in large affiliates, ZGOO Holdings builds its strategy around acquiring small and mid-sized companies led by their founders. Compared with Hanmi Science (Hanmi Science), which is centered on pharmaceutical affiliates, its business base has a different character.

With Neural Arcade and Hanger consolidated, AI consumer content and cosmetics distribution have joined healthcare in the portfolio. These segments have different demand drivers from diagnostics, so the industry picture is hard to view as a single frame.

Cycle position and share versus peers in the healthcare segment are areas to verify against disclosures and industry data.

06

Outlook

In its first-quarter 2026 briefing, the company said profit improvement would become more visible from the second quarter, and it presented a plan to consolidate Neural Arcade in April and Hanger in May to expand revenue.

In the same material, the healthcare segment was pointed to stabilizing sales and improving profit at U2Bio and its clinical trial subsidiary, with a target of about KRW 9 billion in combined sales for the existing segments.

The company plans bolt-on acquisitions within the healthcare value chain and aims to expand consumer AI content around Neural Arcade as an anchor. Collaboration with Noul is at the stage of reviewing the introduction of miLab to domestic hospitals and clinical trial sites, with details to be worked out in phases.

The company filed a voluntary disclosure of its corporate value enhancement plan on May 12, 2026, and a change of CEO was disclosed on August 27, 2026. Whether the acquisition strategy and profit direction continue under the new management is therefore the next point to check.

Because the operating loss narrowed in the second quarter but widened again in the third, whether the profit targets the company has described show up in quarterly results is the central question.

In the 2026 annual report, the next regular filing, the clearest checkpoint will be how the annual operating margin moved from -9.2% in 2025.

07

Valuation

PER
—
PBR
1.0×
ROE
-15.7%
EPS
-₩447
BPS
₩3,414
Dividend per share
₩100

Because attributable net losses have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. The price-to-book ratio, by contrast, sits below 1x, so market capitalization is below the book value of net assets.

Total equity of KRW 42.3 billion at year-end 2025 is entirely attributable to the parent's shareholders, with no non-controlling interests. The debt ratio fell from 50.8% in 2022 to 24.1% in 2025, which eases leverage concerns, but operating cash flow has been negative since 2023 and should be read alongside that.

The company pays a dividend, and whether dividend funding and policy continue through loss periods is a matter to confirm through future disclosures. Past profitable-period multiples are hard to compare directly with the current earnings structure.

The business has broadened from healthcare into consumer content and cosmetics, which also makes it difficult to map onto past valuation benchmarks. How much premium the market places over net asset value appears to depend on the pace of profit recovery and progress in the governance restructuring.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Healthcare cluster linked to Noul

With U2Bio and a clinical sample analysis subsidiary in place, a plan to introduce Noul's miLab to domestic hospitals and clinical trial sites is under review. ZGOO Holdings became the largest shareholder with a stake of about 9.7%. Noul said the investment marks the start of its full entry into domestic diagnostics.

Revenue expansion from consolidation

Second-quarter 2026 sales reached KRW 12 billion, up 72.1% from the prior quarter. The company said Neural Arcade and Hanger would be fully consolidated from April and May. Third-quarter sales of KRW 10.7 billion were up 55.6% year on year, so the top line stayed above the prior year's level.

Shareholder-operated governance model

The attributable net loss narrowed to KRW 2.28 billion in the third quarter from KRW 3.7 billion in the second. The company describes a shareholder group holding about half of the shares and taking part in operations. It also presented a working board model in which major shareholders serve as executive directors.

09

Bear factors

Widening operating losses

The third-quarter 2026 operating loss was KRW 2.22 billion, up sharply from KRW 549 million in the second quarter. Operating losses have continued for five consecutive quarters since the third quarter of 2025. Sales growth year on year has not translated into a narrower operating loss.

Negative cash flow and funding needs

Operating cash flow was negative in every year from 2023 to 2025, at -KRW 1.56 billion in 2025. Subscriptions to Noul shares of KRW 2.75 billion and the Hanger acquisition of KRW 3.87 billion add to a cumulative funding burden. If acquisitions rely on external capital, dilution of shareholder value is also a factor.

Management change and integration costs

A change of CEO was disclosed on August 27, 2026. In the first quarter, one-off integration and restructuring costs linked to the launch of ZGOO Holdings and the acquisition of a clinical trial subsidiary pushed up selling and administrative expenses.

As more subsidiaries are consolidated, integration management becomes harder, so how fast the cost base is streamlined remains a weak point.

10

Risk factors

M&A and integration execution

Several companies, including Neural Arcade, Hanger and Noul, are being brought into the group over a short period, which makes cross-subsidiary linkage and accounting more complex. Consolidation has lifted sales without narrowing the operating loss, so it is hard to isolate each subsidiary's contribution.

The acquisition screen for companies with at least KRW 5 billion in annual sales can also add earnings volatility from acquired businesses.

Cash flow and funding

Operating cash flow has been negative since 2023, and quarterly operating losses have continued for five consecutive quarters. With stake purchases and capital increase participation happening in succession, the need for external funding could grow. If financing relies on new share issuance, existing shareholders' stakes could be diluted.

Governance and strategic direction

With the CEO change in August 2026, it remains to be seen whether the acquisition strategy and healthcare-centered direction continue. A shareholder group holding about half of the shares strengthens operational involvement, but concentrated decision-making also raises checks-and-balances questions. The company says it has independent directors and an audit structure in place.

11

What to watch next

  1. Early 2027 (annual preliminary results, based on past disclosure timing)

    Fourth-quarter and full-year 2026 preliminary operating results are expected. The check is how the full-year contribution of consolidated subsidiaries and the operating loss compare with KRW 2.36 billion in 2025.

  2. Late March 2027 (annual report filing deadline)

    The 2026 annual report will confirm full-year sales, operating margin and attributable net income. The key check is the direction of the operating margin relative to -9.2% in 2025.

  3. Mid-May 2027 (estimated from the first-quarter 2026 briefing schedule)

    The first-quarter 2027 results and briefing will show whether the operating loss narrows and whether the healthcare profit improvement plan appears in quarterly figures.

  4. After November 2026 (timing not set)

    Whether the domestic introduction of Noul's miLab takes concrete form, and how the Noul stake is reflected in accounting in disclosures, are the points to watch.

12

Overall view

ZGOO Holdings is shifting from a holding company centered on diagnostics toward an investment platform built on permanent capital. With Neural Arcade and Hanger consolidated in 2026, sales reached KRW 12 billion in the second quarter and KRW 10.7 billion in the third, both up year on year.

Over the same period the operating loss widened from KRW 549 million in the second quarter to KRW 2.22 billion in the third, and operating losses have continued for five consecutive quarters.

Read together with the 2025 operating loss of KRW 2.36 billion and continued negative operating cash flow, revenue growth has not yet produced cash generation. The attributable net loss narrowed to KRW 2.28 billion in the third quarter, but the total for the last four quarters is KRW 6.94 billion.

Positive factors include the largest-shareholder position in Noul, links within the healthcare cluster, and a shareholder-operated governance structure. Negative factors include continued operating losses, funding needs from acquisitions and capital raises, and uncertainty over strategy after the CEO change.

The next checkpoints are the full-year operating margin and subsidiary contributions confirmed in the 2026 annual report, and whether the operating loss narrows in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. news.nate.com
  2. mt.co.kr
  3. fnnews.com
  4. jobplanet.co.kr
  5. monews.co.kr
  6. kr.investing.com
  7. supple.kr
  8. hankyung.com
  9. biotimes.co.kr
  10. ebn.co.kr
  11. kind.krx.co.kr
  12. butler.works
  13. m.irgo.co.kr
  14. catch.co.kr
  15. judal.co.kr
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis